Abdellatif Abeer Awad, Mogawer Mohamad Sherif, El-Shazli Mostafa, El-Karaksy Hanaa, Salah Ayman, Abdel-Maqsod Amany, El-Amir Mona, Said Mohamed, Zayed Naglaa, Hosny Karim, Eldeen Hadeel Gamal, Osman Ayman M A, Mansour Doaa A, Nabil Ahmed, Abdel-Ghani Ahmed, Mogahed Engy A, Yasin Noha A
Hepatogastroenterology, Liver Transplantation Unit, Internal Medicine Department, Kasr Al-Aini Hospitals, Cairo University, Kasr Al-Aini Street, Cairo, PO: 11451 Egypt.
Department of General Surgery, Liver Transplantation Unit, Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.
Egypt Liver J. 2021;11(1):92. doi: 10.1186/s43066-021-00153-0. Epub 2021 Dec 20.
Solid organ transplantation (SOT) service has been disrupted during the current coronavirus disease 2019 (COVID-19) pandemic, which deferred the service in most centers worldwide. As the pandemic persists, there will be an urgency to identify the best and safest practices for resuming activities as areas re-open. Resuming activity is a difficult issue, in particular, the decision of reopening after a period of slowing down or complete cessation of activities.
To share our experience in resuming living donor liver transplantation (LDLT) in the context of the COVID-19 pandemic in the Liver Transplantation Unit of El-Manial Specialized Hospital, Cairo University, Egypt, and to review the obstacles that we have faced.
This study is a single-center study. We resumed LDLT by the 26th of August 2020 after a period of closure from the 1st of March 2020. We have taken a lot of steps in order to prevent COVID-19 transmission among transplant patients and healthcare workers (HCWs).
In our study, we reported three LDLT recipients, once resuming the transplantation till now. All our recipients and donors tested negative for SARS-CoV-2 by nasopharyngeal RT-PCR a day before the transplantation. Unfortunately, one of them developed COVID-19 infection. We managed rapidly to isolate him in a single room, restricting one team of HCWs to deal with him with strict personal protective measures. Finally, the patient improved and was discharged in a good condition. The second patient ran a smooth course apart from FK neurotoxicity which improved with proper management. The third patient experienced a sharp rise in bilirubin and transaminases on day 14 that was attributed to drug toxicity vs. rejection and managed by discontinuing the offending drugs and pulse steroids. In addition, one of our head nurses tested positive for SARS-CoV-2 that was manageable with self-isolation.
Careful patient, donor, personnel screening is mandatory. Adequate supply of personal protective equipments, effective infection control policies, and appropriate administrative modifications are needed for a safe return of LDLT practice.
在当前的2019冠状病毒病(COVID-19)大流行期间,实体器官移植服务受到干扰,全球大多数中心都推迟了该服务。随着大流行的持续,随着各地区重新开放,迫切需要确定恢复活动的最佳和最安全做法。恢复活动是一个难题,特别是在活动放缓或完全停止一段时间后重新开放的决定。
分享埃及开罗大学埃尔马尼亚尔专科医院肝脏移植科在COVID-19大流行背景下恢复活体肝移植(LDLT)的经验,并回顾我们所面临的障碍。
本研究为单中心研究。在2020年3月1日关闭一段时间后,我们于2020年8月26日恢复了LDLT。我们采取了很多措施来预防COVID-19在移植患者和医护人员之间传播。
在我们的研究中,自恢复移植以来,我们报告了3例LDLT受者。我们所有的受者和供者在移植前一天通过鼻咽RT-PCR检测SARS-CoV-2均为阴性。不幸的是,其中一人感染了COVID-19。我们迅速将他隔离在一个单人房间,限制一组医护人员用严格的个人防护措施来护理他。最后,患者病情好转并康复出院。第二名患者除了FK神经毒性外,病程顺利,通过适当管理病情有所改善。第三名患者在第14天胆红素和转氨酶急剧升高,这归因于药物毒性与排斥反应,通过停用相关药物和脉冲类固醇进行处理。此外,我们的一名护士长SARS-CoV-2检测呈阳性,通过自我隔离可控制病情。
对患者、供者、人员进行仔细筛查是必要的。为了安全恢复LDLT实践,需要充足的个人防护设备供应、有效的感染控制政策和适当的行政调整。